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The concept of pathologic complete response (pCR) has been an enigmatic one, often at the center of much debate and controversy. While most researchers would agree that the absence of residual invasive carcinoma in the breast and axilla is imperative in defining pCR, the impact of residual in situ tumor is still debated. The current AJCC 8 th Edition defines pCR as the absence of any residual invasive carcinoma in the breast/axilla/lymph vessels. The presence of in situ tumor in the absence of invasive carcinoma still constitutes a pCR. [1] From the early studies onward, pCR showed great promise in its ability to predict outcomes after chemotherapy. This association was strongest in aggressive biology tumors, such as triple-negative and HER2-positive cancers. [2] Researchers surmised that pCR could potentially be a surrogate marker for survival. Based on its ability to improve pCR rates, [3] pertuzumab was the first drug to receive accelerated approval from the Food and Drug Administration in 2013. The corresponding adjuvant trial (APHINITY) demonstrated only a marginal improvement in disease-free survival (94.1% vs. 93.2%, P = 0.045) in its early analysis, and further maturing of data is awaited. Along similar lines, addition of lapatinib improved pCR rates significantly; however, in the adjuvant setting, it failed to impact survival outcomes. [4, 5] The CTNeoBC meta-analysis [6] funded by the US-FDA confirmed the prognostic value of pCR, especially in aggressive tumor subtypes; however, it could not validate pCR as a surrogate endpoint for survival.
Following this, pCR continued to simmer for a while and found its clinical application in its ability to prognosticate aggressive subtypes. However, the recent turn of events, specifically the CREATE-X [7] and KATHERINE [8] trials, has demonstrated, a hitherto unexplored, predictive capability of pCR. The CREATE-X study suggested a survival benefit with the addition of capecitabine, in women with triple-negative breast cancer, with residual disease post-neoadjuvant chemotherapy (NACT). Likewise, the early analysis of KATHERINE points toward a benefit in invasive disease-free survival with Trastuzumab emtansine over trastuzumab, in HER2-positive breast cancers with residual disease post-NACT. In both these studies, pCR, or more specifically, the lack of it, was used as a marker to tailor adjuvant therapy, with improved outcomes. Dear Editor, Lung cancer treatment is a rapidly evolving and an excellent example of precision medicine. The outcome of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) has improved significantly with recent report showing the survival of 56% at 4 years. [1] This has been possible due to the availability of effective sequential treatment.
Letter to the Editor
One of the important drugs has been lorlatinib. This has found to be effective in second-line setting after crizotinib. [2] There has been no data from India. We retrospectively analyzed the data of patients receiving lorlatinib in our hospital. Patients diagnosed with ALK-positive advanced NSCLC who have received lorlatinib between January 2018 and February 2019 patients who have progressed on crizotinib were included in the study. Lorlatinib (Pfizer Oncology, Groton, CT, USA) was administered orally in a tablet form at a starting dose of 100 mg once daily continuously in 21-day cycles.
The details of these patients were obtained from the prospective lung cancer audit database that is maintained in the department of medical oncology. Demography (age, gender, comorbidity, and smoking status), disease status, and therapy details were recorded. ALK amplified status was ascertained either by immunohistochemistry (monoclonal antibody D5F3 [Ventana Medical Systems, Tucson, AZ, USA]) or fluorescent in situ hybridization analysis (Abbott Molecular platform). Response assessment was performed every 2-4 months as per the (Continue on page 217...) 
